MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 126813 | Name: Pumosetrag

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pumosetrag is a novel, orally active and selective 5-HT 3 agonist.

Chemical Structure

Pumosetrag
Pumosetrag
CAS#153062-94-3 (free base)

Theoretical Analysis

MedKoo Cat#: 126813

Name: Pumosetrag

CAS#: 153062-94-3 (free base)

Chemical Formula: C15H17N3O2S

Exact Mass: 303.1041

Molecular Weight: 303.38

Elemental Analysis: C, 59.39; H, 5.65; N, 13.85; O, 10.55; S, 10.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
153062-94-3 (free base) 194093-42-0 (HCl)
Synonym
PUMOSETRAG; Pumosetrag [INN]; DDP 733; DDP-733; DDP733
IUPAC/Chemical Name
(R)-7-oxo-N-(quinuclidin-3-yl)-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide
InChi Key
AFUWQWYPPZFWCO-LBPRGKRZSA-N
InChi Code
InChI=1S/C15H17N3O2S/c19-13-10(7-16-11-3-6-21-14(11)13)15(20)17-12-8-18-4-1-9(12)2-5-18/h3,6-7,9,12H,1-2,4-5,8H2,(H,16,19)(H,17,20)/t12-/m0/s1
SMILES Code
O=C(N[C@H]1CN2CCC1CC2)C3=CNC4=C(SC=C4)C3=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 303.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Choung RS, Locke GR 3rd, Francis DD, Katzka D, Winkle PJ, Orr WC, Crowell MD, Devault K, Harmsen WS, Zinsmeister AR, Talley NJ. Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study. Neurogastroenterol Motil. 2014 Jan;26(1):13-20. doi: 10.1111/nmo.12214. PubMed PMID: 24001105. 2: Evangelista S. Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Investig Drugs. 2007 May;8(5):416-22. Review. PubMed PMID: 17520871. 3: Chai W, Chan KY, de Vries R, van den Bogeardt AJ, de Maeyer JH, Schuurkes JA, Villalón CM, Saxena PR, Danser AH, MaassenVanDenBrink A. Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae. Life Sci. 2012 Apr 9;90(13-14):538-44. doi: 10.1016/j.lfs.2012.01.009. PubMed PMID: 22326501. 4: Chetty N, Irving HR, Coupar IM. Effects of the novel 5-HT3 agonist MKC-733 on the rat, mouse and guinea pig digestive tract. Pharmacology. 2008;81(2):104-9. PubMed PMID: 17952012. 5: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PubMed PMID: 19088949. 6: Fujita T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther. 2005 Dec;30(6):611-22. PubMed PMID: 16336295. 7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Apr;28(3):185-206. PubMed PMID: 16810345. 8: Coleman NS, Marciani L, Blackshaw E, Wright J, Parker M, Yano T, Yamazaki S, Chan PQ, Wilde K, Gowland PA, Perkins AC, Spiller RC. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther. 2003 Nov 15;18(10):1039-48. PubMed PMID: 14616171.

View History

PUN 90488

PUN 90488

Featured